Hemcheck Sweden AB and Capio S:t Göran’s hospital have, as earlier communicated, finalised the study at the emergency care unit, to evaluate if Hemcheck’s product concept can lower the hemolysis rate in hemolysis sensitive blood samples sent to the central laboratory. As one part of the evaluation of the results, an anonymised user survey has been performed to understand how users in more detail have used the product concept and how they evaluate it as a supporting tool in their daily work.
The results from the user survey show, among other things, that 100% of respondents want to continue using the product concept and that 93% recommends other healthcare units to use it.
–Its very positive that the users are so positive and supportive of our product concept. Since we introduce a new work step, it has beforehand not been self evident that the users should without exception be so positive to our product concept, even if it in total creates much more value such as shortened lead times and better patient care. We have in addition gotten good feedback from the user survey on potential adjustments in how the product concept is used, with potential to additionally improve the results regarding lowering the frequency of hemolyzed blood samples reaching the central laboratory, says Joen Averstad, CEO of Hemcheck.
–Its very positive that the personnel that have used the product concept are so satisfied and positive, since their input is an important part of how we evaluate potential improvements in our department. It’s also very positive feedback to the study in general, says Ylva Grönneberg, deputy care unit manager, Acute clinic Capio S:t Göran’s Hospital.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Capio S:t Göran’s Hospital
Capio S:t Göran’s Hospital is an emergency hospital for adult patients, located at Kungsholmen in Stockholm. The hospital is Stockholm’s most centrally located emergency hospital and one of the country’s largest in terms of the number of emergency patients. In 2019, more than 100,000 visits were done at the emergency care unit. Capio S:t Göran’s Hospital is part of Capio, which in turn is part of Ramsay Générale de Santé, a leading European healthcare provider operating 235 hospitals around the world.
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.